TRB’s Swiss industrial site, based in Vouvry, is mainly made up of two production units:
One is dedicated to the gangliosides* extraction and the second one to the manufacturing of hyaluronic acid based injectable products. The factory also owns a Research and Development unit which works closely with the production division. All TRB’s on-site innovative production methods and procedures are designed and implemented by the same R&D department. Thanks to our cutting-edge equipment, the company has achieved a high level of expertise in biotechnology, molecular biology, chemical extraction, synthesis and, finally, galenic. Our exclusive use of high quality ingredients ensures the excellence of TRB’s products, always with respect of the environment.
TRB’s hyaluronic acid based injectable products division and the GM1* production sites were developed and created by the plant’s technical department in accordance with applicable Good Manufacturing Practices (GMP) requirements. The technical department based at the factory boosts our flexibility and our integration capacity, whilst also strengthening TRB’s independence in development and engineering. The isolation and purification process of gangliosides and monosialogangliosides were both entirely developed and scaled up at the Vouvry site. The ganglioside powder, used as a main raw material for GM1*, is obtained after several cleaning, extraction and purification steps, based on the TRB’s biotech know-how.
We have two production sites in Latin America. Our plant in Brazil was established in 1989, and our plant in Argentina in 1992.
Our South American teams are responsible for manufacturing a wide array of products for rheumatology, pain relief and neurology*.
Both South American plants meet the international GMP standard, as does our main plant in Switzerland.